BioLife Solutions, Inc.

Equities

BLFS

US09062W2044

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2024 BST			5-day change	1st Jan Change
22.51 ^USD	-1.14%		+16.57%	+38.52%

05-29	BioLife Solutions Introduces the CellSeal CryoCase? at International Society for Cell & Gene Therapies Conference in Vancouver	CI
05-13	Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target	MT

Biolife Solutions, Inc. Reports Preliminary Revenue Results for the Full Year 2013

January 06, 2014 at 11:00 am

BioLife Solutions, Inc. announced preliminary revenue of $9.0 million for the full year 2013. This represents 58% growth over 2012, driven by increased shipments to a large contract-manufacturing customer and expanded adoption of CryoStor(R) freeze media and HypoThermosol(R) storage/shipping media in clinical trial stage cell-based regenerative medicine products and therapies.

Latest news about BioLife Solutions, Inc.

BioLife Solutions Introduces the CellSeal CryoCase? at International Society for Cell & Gene Therapies Conference in Vancouver	05-29	CI
Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target	05-13	MT
Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, vs. Street Est of $24.9M	05-09	MT
Transcript : BioLife Solutions, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
BioLife Solutions, Inc. Affirms Revenue Guidance for the Year 2024	05-09	CI
BioLife Solutions, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
BioLife Solutions Completes Divestment of Global Cooling Subsidiary	04-18	MT
An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. for $2.6 million.	04-17	CI
Jefferies Initiates Coverage on BioLife Solutions With Buy Rating, $22 Price Target	04-04	MT
BioLife Solutions, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Transcript : BioLife Solutions, Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
BioLife Solutions, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Biolife Solutions Announces Preliminary Unaudited Revenue Results for Fourth Quarter and Full Year 2023	01-08	CI
Lake Street Adjusts BioLife Solutions Price Target to $15 From $25, Maintains Buy Rating	11-10	MT
Transcript : BioLife Solutions, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
BioLife Solutions, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Casdin Capital Engages in Discussions with BioLife Solutions	24/10/23	CI
BioLife Solutions Names New CEO; Sees 2023 Revenue at Low End of Guidance	19/10/23	MT
BioLife Solutions, Inc. Announces Chief Executive Officer Changes	19/10/23	CI
BioLife Solutions, Inc. Announces Management Changes	19/10/23	CI
BioLife Solutions, Inc. Revises Earnings Guidance for the Full Year 2023	19/10/23	CI
BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC	18/10/23	CI
Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating	09/08/23	MT
Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023	08/08/23
Biolife Solutions, Inc. Provides Earnings Guidance for the Year 2023	08/08/23	CI

Chart BioLife Solutions, Inc.

Duration

Period

More charts

Company Profile

BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Its expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. Its biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death which result when cells and tissues are subjected to reduced temperatures. Its bioproduction tools portfolio includes human platelet lysates for cell expansion. It is a provider of biological and pharmaceutical storage and cold chain logistics. Its monitoring systems allow customers real time tracking of the storage temperatures of their materials throughout the logistics process. It operates about five storage facilities in the United States and one facility in the Netherlands.

Sector

Medical Equipment, Supplies & Distribution

Calendar

21/07/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BioLife Solutions, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.51 USD

Average target price

25.44 USD

Spread / Average Target

+13.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BIOLIFE SOLUTIONS, INC.	+38.52%	1.04B
ABBOTT LABORATORIES	-4.90%	182B
MEDTRONIC PLC	-1.36%	104B
DEXCOM, INC.	-7.64%	45.58B
HOYA CORPORATION	+10.24%	46.44B
CENCORA, INC.	+9.63%	44.34B
METTLER-TOLEDO INTERNATIONAL, INC.	+13.63%	29.44B
TERUMO CORPORATION	+20.60%	26.8B
WEST PHARMACEUTICAL SERVICES, INC.	-7.12%	23.82B
STERIS PLC	+4.03%	22.61B

Other Medical Equipment, Supplies & Distribution